SCHEMBL6903656

SCHEMBL6903656

CC(C=CO)N1CCN(c2cccc3c2CCc2ccccc2C3)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.37
DRD3 P35462 6/20 0.35
HTR1A P08908 4/20 0.35
HTR6 P50406 2/20 0.35
HTR7 P34969 2/20 0.35
ADRA2A P08913 1/20 0.35
ADRA2B P18089 1/20 0.35
ADRA2C P18825 1/20 0.35
SLC6A2 P23975 1/20 0.35
HTR1D P28221 1/20 0.35
HTR1B P28222 1/20 0.35
HTR2A P28223 1/20 0.35
HRH1 P35367 1/20 0.35
HTR2B P41595 1/20 0.35
GAA P10253 1/20 0.35
DRD2 P14416 7/20 0.35
DRD1 P21728 4/20 0.35
DRD5 P21918 4/20 0.35
DRD4 P21917 3/20 0.35
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6461339 0.75 ATM (0.32) ATMDRD3HTR1AHTR6HTR7
SCHEMBL6466061 0.71 DRD2 (0.38) DRD3HTR1AHTR2AGAADRD2
SCHEMBL1444940 0.71 HTR6 (0.49) DRD3HTR1AHTR6HTR7HTR1D
SCHEMBL6460817 0.70 DRD2 (0.41) DRD3HTR1AHTR2AGAADRD2
SCHEMBL5675675 0.69 DRD2 (0.41) DRD3HTR1AHTR6HTR7ADRA2A
SCHEMBL6463756 0.69 DRD2 (0.42) DRD3HTR1AADRA2AADRA2BADRA2C
SCHEMBL6462545 0.68 DRD2 (0.39) DRD3HTR1AHTR2AGAADRD2
SCHEMBL9403868 0.68 L3MBTL1 (0.58) HTR7GAAMEN1KMT2ASMN1; SMN2
SCHEMBL6465693 0.68 HTR1A (0.45) ATMDRD3HTR1AHTR6HTR7
SCHEMBL6463464 0.67 DRD2 (0.39) DRD3HTR1AHTR2AGAADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040029895-A1 Dibenzosberanyl piperazine derivatives and drug-resistance overcoming agents containing the derivatives TAKAYANAGI, HIROAKI (JP) 2004-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040029895-A1 Dibenzosberanyl piperazine derivatives and drug-resistance overcoming agents containing the derivatives ABCC1, ABCB1, SLC11A2 ATM 3208/4885DRD3 1857/4885HTR1A 3114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.